Manchester Capital Management’s Charles River Laboratories CRL Stock Holding History

Manchester Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.03K	Hold	6	–	–	﹤0.01%	1125
2025 Q4	$1.2K	Sell	6 -10	-63%	-$1.81K	﹤0.01%	1106
2025 Q3	$2.5K	Hold	16	–	–	﹤0.01%	1049
2025 Q2	$2.43K	Buy	16 +15	+1,500%	+$2K	﹤0.01%	983
2025 Q1	$151	Sell	1 -95	-99%	-$15.9K	﹤0.01%	1148
2024 Q4	$17.7K	Buy	96 +22	+30%	+$4.24K	﹤0.01%	722
2024 Q3	$14.6K	Buy	74 +50	+208%	+$10.4K	﹤0.01%	736
2024 Q2	$4.96K	Buy	+24	New	+$5.44K	﹤0.01%	847
2021 Q3	–	Sell	-45	Closed	-$17K	–	1047
2021 Q2	$17K	Buy	+45	New	+$15K	﹤0.01%	452
2021 Q1	–	Sell	-3	Closed	-$1K	–	673
2020 Q4	$1K	Buy	+3	New	+$714	﹤0.01%	643

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Manchester Capital Management's CRL Position: Q1 2026 in Review

Manchester Capital Management held its Charles River Laboratories (CRL) position steady in Q1 2026 at 6 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Manchester Capital Management first reported a position in CRL in Q4 2020 and has held it in 10 quarters since. The position peaked at $17.7K in Q4 2024. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Manchester Capital Management held 6 shares of Charles River Laboratories worth $1.03K as of Q1 2026.
Manchester Capital Management left its Charles River Laboratories share count unchanged in Q1 2026.
Charles River Laboratories made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #1125 holding.
Manchester Capital Management first reported a position in Charles River Laboratories in Q4 2020 and has held it in 10 quarters since.
Manchester Capital Management's Charles River Laboratories position peaked at $17.7K in Q4 2024.
558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.